Alpha Tau Medical Ltd. DRTS
14.04 USD +0.34 (+2.45%)
Nov 11, 2026, 3:57 PM EST
14.00 Day range 14.59
3.43 52-week range 15.79
- YTD
- +183.54%
- 1 year
- +256.22%
News
benzinga.com This Apple Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded RSG, AAPL, MRCY, DK and DRTS, revising price targets, including AAPL to $425 and DRTS to $22.
benzinga.com Piper Sandler Upgrades Alpha Tau Medical to Overweight, Raises Price Target to $22 Piper Sandler analyst Allison Bratzel upgrades Alpha Tau Medical (NASDAQ:DRTS) from Neutral to Overweight and raises the price target from $8 to $22.
benzinga.com Alpha Tau Medical To Join TASE’s TA-90 and TA-125 Indices On November 5, 2026 Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdingsTA-125 tracks the 125 largest and most prominent companies on the TASEJERUSALEM, Oct. 29, 2026…
benzinga.com Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the signing of an MOU in Seoul, South Korea,…
benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.
benzinga.com Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the U.S. Food and Drug Administration…- benzinga.com Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30 Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and raises the price target from $17 to $30.
benzinga.com HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16 HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $15 to $16.- benzinga.com Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.14) by 257.14 percent. This is a 284.62 percent decrease over losses…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
- benzinga.com Alpha Tau Medical Announces Positive Data In Head And Neck Cancer Treatment Study, Hitting 100% Objective Response Rate Across Nine Evaluable Patients Response RateAmong evaluable patients, treatment with Alpha DaRT plus pembrolizumab produced an objective response rate (i.e., systemic complete response plus partial response) of 100%, including…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million. Kalaris Therapeutics (NASDAQ:KLRS)…
benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
benzinga.com Alpha Tau Medical Treats First Patient In ADMIRE Study, Clinical Trial Evaluating Intratumoral Alpha DaRT For Immunocompromised Patients With Recurrent Cutaneous Squamous Cell Carcinoma - The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which…- benzinga.com Alpha Tau Medical Announces Success Treatment With Alpha DaRT Of First Glioblastoma Patient In Israel Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the successful treatment with Alpha DaRT of the…
- benzinga.com Alpha Tau Medical Receives FDA Clearance To Proceed With Enrollment Of Final Seven Patients In U.S. REGAIN Trial - Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
benzinga.com Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $17 Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and raises the price target from $15 to $17.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELYB, NN, BVC, MX, ECX, DRTS, RZLT, SYRE, TGTX.- benzinga.com Alpha Tau Medical and Tolmar Form U.S. Prostate Cancer Partnership To Commercialize Alpha DaRT Therapy With Exclusive Rights And Long-Term Revenue Sharing Deal - Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
- benzinga.com Alpha Tau Medical Presents Overall Survival, Safety Results From Pooled Analysis Of Three Prospective Phase I/II Clinical Studies Evaluating EUS-Guided Intratumoral Alpha Dart Treatment In PDAC Patients At 2026 ASCO Annual Meeting - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey -- Pooled analysis of…
- benzinga.com Barclays Initiates Coverage On Alpha Tau Medical with Overweight Rating, Announces Price Target of $15 Barclays analyst Lukas Shumway initiates coverage on Alpha Tau Medical (NASDAQ:DRTS) with a Overweight rating and announces Price Target of $15.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
- benzinga.com Piper Sandler Maintains Neutral on Alpha Tau Medical, Raises Price Target to $8 Piper Sandler analyst Jason Bednar maintains Alpha Tau Medical (NASDAQ:DRTS) with a Neutral and raises the price target from $5 to $8.
benzinga.com CORRECTION: Alpha Tau Medical Q1 EPS $(0.26) Misses $(0.12) Estimate Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.12) by 116.67 percent. This is a 116.67 percent decrease over losses…- benzinga.com Ladenburg Thalmann Maintains Buy on Alpha Tau Medical, Raises Price Target to $14 Ladenburg Thalmann analyst Jeff Cohen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $12 to $14.
- benzinga.com HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $15 HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $12 to $15.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally Alpha Tau Medical stock surged after interim glioblastoma data showed complete responses in two patients treated with Alpha DaRT.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com Alpha Tau Medical Treats First Pancreatic Cancer Patient In Feasibility And Safety Study For Alpha-Emitter Radiation Treatment For Pancreatic Tumors By enabling two complementary delivery pathways - endoscopic ultrasound (EUS) and percutaneous - within a single protocol, the study aims to bring interventional radiologists and interventional…
- benzinga.com Alpha Tau Medical Announces Presentation Of Updated Pooled Results From Two First-In-Human Clinical Trials Of Alpha Dart In Pancreatic Ductal Adenocarcinoma At Digestive Disease Week - 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT® in pancreatic adenocarcinoma -- Favorable safety profile observed, with…
- benzinga.com Alpha Tau Medical Says Abstract Showcasing Combined Results From Three Clinical Studies Evaluating Alpha Radiotherapy For Advanced Pancreatic Cancer Accepted At 2026 ASCO Annual Meeting - Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world's largest and most prestigious medical oncology conference -- Pooled analysis combines safety and…
- benzinga.com Alpha Tau Medical Announces FDA Approval Of Investigational Device Exemption Supplement To Its U.S. IMPACT Trial Evaluating Alpha DaRT To Treat Unresectable Locally Advanced Or Metastatic Pancreatic Adenocarcinoma Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that the FDA has approved an Investigational…
- benzinga.com Alpha Tau Medical Announces Treatment Of First Patient In ACAPELLA, European Multicenter Clinical Trial Evaluating Alpha DaRT Combined With Capecitabine For Patients With Inoperable LAPC ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line…
- benzinga.com Citigroup Maintains Buy on Alpha Tau Medical, Raises Price Target to $9 Citigroup analyst Yigal Nochomovitz maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $7 to $9.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $12 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $12 price target.
- benzinga.com Alpha Tau Medical Q4 EPS $(0.14) Misses $(0.12) Estimate Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 13.82 percent. This is a 7.69 percent decrease over losses of…
- benzinga.com Piper Sandler Downgrades Alpha Tau Medical to Neutral, Maintains Price Target to $5 Piper Sandler analyst Jason Bednar downgrades Alpha Tau Medical (NASDAQ:DRTS) from Overweight to Neutral and maintains the price target from $5 to $5.
- benzinga.com HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $12 HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $9 to $12.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com TG Therapeutics, Clover Health Investments, Nutrien And Other Big Stocks Moving Higher On Wednesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.